# Cencora (COR) Q4 FY2026 earnings

Results filed 2026-11-04 for the quarter ended 2026-09-29. Source page: https://earnings.opennash.com/companies/cor/2026-q4/
Press release and documents: https://www.sec.gov/Archives/edgar/data/1140859/000114085926000038/0001140859-26-000038-index.htm
> Summaries and transcripts are machine-generated and can contain errors.

## In brief

Cencora is reorganizing into two customer-focused segments and buying American Oncology Network, deepening its bet on specialty and oncology physician practices after closing OneOncology.

Cencora closed its OneOncology acquisition in February 2026, adding a physician-practice platform that lifted U.S. profitability. Specialty product sales to health systems and physician practices grew, as did GLP-1 sales, which carry lower margins. Brand manufacturer price declines and lower sales to its large mail order customer partly offset growth. It also sold U.S. Consulting Services in April 2026.
Management is moving to a new operating model with Pharmaceutical Distribution and Services and Specialty Pharmaceutical and Provider Services segments, and plans to add American Oncology Network, a network of more than 350 oncology providers across 21 states. It is also selling Profarma and expects MWI Animal Health to merge with Covetrus. The tension is integrating several acquisitions and divestitures while GLP-1 mix dilutes distribution margins.

## Key numbers

| Metric | Value | Change | Basis |
| --- | --- | --- | --- |
| Q4 revenue | $88.4 billion | up 5.5 percent | GAAP |
| Q4 diluted EPS | $2.71 | compared to $(1.75) in the prior year quarter | GAAP |
| Q4 adjusted diluted EPS | $4.66 | increased 21.4 percent | non-GAAP |
| Q4 adjusted operating income | $1.2 billion | 22.1 percent increase | non-GAAP |
| FY2026 operating cash flow | $4,790M |  | GAAP |

## Segments and operating metrics

| Name | Value | Change |
| --- | --- | --- |
| U.S. Healthcare Solutions revenue | $78.3 billion | up 5.4 percent |
| International Healthcare Solutions revenue | $7.8 billion | up 5.1 percent |
| Other revenue | $2.3 billion | up 10.1% |

## Outlook

| Metric | Period | Outlook |
| --- | --- | --- |
| Revenue growth | fiscal 2027 | 3% to 5% growth |
| Adjusted diluted EPS | fiscal 2027 | $19.40 to $19.75 |
| Adjusted operating income growth | fiscal 2027 | 4% to 6% growth |
| Net interest expense | fiscal 2027 | $490M to $510M |
| Adjusted effective tax rate | fiscal 2027 | ~20% |
| Adjusted free cash flow | fiscal 2027 | ~$3.5B |
| Capital expenditures | fiscal 2027 | ~$1.0B |

## Key takeaways

1. **Cencora restructures into two customer-focused segments** From fiscal 2027 it will report Pharmaceutical Distribution and Services and Specialty Pharmaceutical and Provider Services, plus Other. Management says the model is meant to strengthen execution and improve visibility.
2. **American Oncology Network deal extends oncology push** Cencora signed a definitive agreement to acquire a physician-led network of more than 350 oncology providers across 21 states. It follows the February 2026 OneOncology acquisition.
3. **Specialty and physician practice demand drives U.S. volume** U.S. growth came from unit volume, including specialty products sold to health systems and physician practices, plus GLP-1 products. Brand manufacturer price declines and lower sales to its large mail order customer partly offset this.
4. **GLP-1 growth dilutes distribution margins** Increased GLP-1 sales carry lower gross profit margins and partly offset the margin benefit from OneOncology. This shows the mix tension in core distribution.
5. **Portfolio pruning continues with Profarma and MWI** Cencora signed to sell its Profarma stake, expected to close in the first quarter of fiscal 2027, and assumes MWI Animal Health merges with Covetrus by March 31, 2027. It divested U.S. Consulting Services in April 2026.

## Questions

**What is Cencora's new segment structure?** Starting in the first quarter of fiscal 2027, it will report Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other. The specialty segment covers physician practice and MSO services, World Courier, 3PL, Innomar and parts of PharmaLex.
**What acquisition did Cencora announce?** It signed a definitive agreement to acquire American Oncology Network, a physician-led network of more than 350 oncology providers across 21 states. This builds on the OneOncology acquisition completed in February 2026.
**What is driving U.S. demand?** Unit volume growth, including specialty product sales to health systems and physician practices and GLP-1 products. Lower brand manufacturer prices and reduced sales to its large mail order customer partly offset it.
**What is happening to Profarma and MWI Animal Health?** Cencora signed to sell its Profarma stake, expected to close in the first quarter of fiscal 2027. Its fiscal 2027 outlook assumes the MWI Animal Health merger with Covetrus closes March 31, 2027.
**What are Cencora's long-term segment targets?** It targets mid-single digit operating income growth for Pharmaceutical Distribution and Services and mid-teens for Specialty Pharmaceutical and Provider Services. It reaffirmed 7% to 10% adjusted operating income growth overall.

## Slides and investor documents

- [Presentation](https://s203.q4cdn.com/785768684/files/content_files/Q4-FY26-Earnings-Presentation-vF.pdf) (Slide deck)
- [Webcast](https://events.q4inc.com/attendee/530038945) (Webcast replay)
- [News Release](https://s203.q4cdn.com/785768684/files/doc_news/Cencora-Reports-Fiscal-2026-Fourth-Quarter-and-Fiscal-Year-End-Results-2026.pdf) (Document)
- [Revised Reportable Segment Information](https://s203.q4cdn.com/785768684/files/content_files/Exhibit-99-1-Resegmentation-vF.pdf) (Document)

